Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Do-It-Yourself Dermatology

This article was originally published in Start Up

Executive Summary

As venture capitalists begin counting cosmetics and aesthetics companies as part of their portfolios, they're also migrating toward investing in consumer-oriented companies including those that make aesthetic devices to be used in the home.

You may also be interested in...



Business and Technology Briefs

Brief summaries of recent product and company developments in the device industry, including a rift in the orthopedics industry following the DOJ settlement, new OTC aesthetics devices, and MannKind's prospects for partnering its inhaled insulin.

Business and Technology Briefs

Brief summaries of recent product and company developments in the device industry, including a rift in the orthopedics industry following the DOJ settlement, new OTC aesthetics devices, and MannKind's prospects for partnering its inhaled insulin.

Light Dimensions Inc.

Might a $200 handheld skin rejuvenation device for home use and sold primarily through a 30-minute infomercial be the key to riches for investors? Light Dimensions' founders and backers hope so. A 2005 entrant into the booming home-use aesthetic device market, Light Dimensions has launched its first product, the LED-based RejuvaWand for minimizing visible signs of aging.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel